Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Sep 15;130(18):3219-3228.
doi: 10.1002/cncr.35374. Epub 2024 Jun 24.

Acupuncture for hot flashes in hormone receptor-positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials

Weidong Lu  1 , Anita Giobbie-Hurder  2 , Anna Tanasijevic  1 , Sylvia Baedorf Kassis  3 , Sung Hwan Park  4 , Young Ju Jeong  4 , Im Hee Shin  5 , Chang Yao  6 , Hyun Jung Jung  7 , Zhiyuan Zhu  6 , Chao Bao  6 , Ting Bao  1 , EunMee Yang  1 , Barbara E Bierer  3   8 , Jennifer A Ligibel  1
Affiliations
Free article
Randomized Controlled Trial

Acupuncture for hot flashes in hormone receptor-positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials

Weidong Lu et al. Cancer. .
Free article

Abstract

Background: Hot flashes are a common side effect of endocrine therapy (ET) that contribute to poor quality of life and decreased treatment adherence.

Methods: Patients with breast cancer wo were receiving ET and experiencing hot flashes were enrolled through three parallel, randomized trials conducted in the United States, China, and South Korea. Participants were randomized to either immediate acupuncture (IA) or delayed acupuncture control (DAC). IA participants received 20 acupuncture sessions over 10 weeks, whereas DAC participants received usual care, then crossed over to acupuncture with a reduced intensity. The primary end point was a change in score on the endocrine symptom subscale of the Functional Assessment of Cancer Therapy (FACT)-Endocrine Symptoms between baseline and week 10. Secondary end points included the hot flash score and the FACT-Breast score. A planned pooled analysis of individual patient data was performed using longitudinal mixed models.

Results: In total, 158 women with stage 0-III breast cancer were randomized (United States, n = 78; China, n = 40; South Korea, n = 40). At week 10, IA participants reported statistically significant improvements in the endocrine symptom subscale score (mean change ± standard error: 5.1 ± 0.9 vs. 0.2 ± 1.0; p = .0003), the hot flash score (-5.3 ± 0.9 vs. -1.4 ± 0.9; p < .003), and the FACT-Breast total score (8.0 ± 1.6 vs. -0.01 ± 1.6; p = .0005) compared with DAC participants. The effect of the acupuncture intervention differed by site (p = .005).

Conclusions: Acupuncture led to statistically and clinically meaningful improvements in hot flashes, endocrine symptoms, and breast cancer-specific quality of life in women undergoing ET for breast cancer in the United States, China, and South Korea.

Keywords: acupuncture therapy; breast neoplasms; cross‐over studies; endocrine therapy; hot flashes; multicenter study; quality of life; randomized controlled trials; symptom assessment; treatment outcome.

PubMed Disclaimer

References

REFERENCES

    1. International Agency for Research on Cancer (IARC), World Health Organization (WHO). Breast cancer. IARC; 2023. Accessed May 10, 2023. https://www.iarc.who.int/cancer‐type/breast‐cancer/
    1. Pan H, Gray R, Braybrooke J, et al. 20‐year risks of breast‐cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836‐1846. doi:10.1056/NEJMoa1701830
    1. Davies C, Pan H, Godwin J, et al. Long‐term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor‐positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805‐816. doi:10.1016/s0140‐6736(12)61963‐1
    1. Wagner LI, Zhao F, Goss PE, et al. Patient‐reported predictors of early treatment discontinuation: treatment‐related symptoms and health‐related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Res Treat. 2018;169(3):537‐548. doi:10.1007/s10549‐018‐4713‐2
    1. Hershman DL, Kushi LH, Hillyer GC, et al. Psychosocial factors related to non‐persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat. 2016;157(1):133‐143. doi:10.1007/s10549‐016‐3788‐x

Publication types

Substances

LinkOut - more resources